Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review.
A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
Pathology case of the month. A recurrent vesicle on the plantar aspect of the foot. Primary cutaneous CD30- positive T-cell lymphoproliferative disorder, consistent with lymphomatoid papulosis.
Cutaneous T-cell lymphomas-An update 2021.
Kempf W, Mitteldorf C.
Hematol Oncol. 2021 Jun;39 Suppl 1:46-51. doi: 10.1002/hon.2850.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
Cutaneous CD30-Positive Lymphoproliferative Disorders.
Kempf W.
Surg Pathol Clin. 2014 Jun;7(2):203-28. doi: 10.1016/j.path.2014.02.001.
Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S.
Pathologie (Heidelb). 2023 Dec;44(Suppl 3):136-139. doi: 10.1007/s00292-023-01258-6. Epub 2023 Nov 27.
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W, Kerl K, Mitteldorf C.
Semin Cutan Med Surg. 2018 Mar;37(1):24-29. doi: 10.12788/j.sder.2018.001.
A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W.
Semin Diagn Pathol. 2017 Jan;34(1):22-35. doi: 10.1053/j.semdp.2016.11.005. Epub 2016 Nov 29.
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ.
Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10.
CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L, Zain J, Rosen ST, Querfeld C.
Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.
Clinicopathological analysis of primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoproliferative disorder: a retrospective study of 22 patients.
Shi HZ, Zhang J, Xiong JS, Gan L, Jiang YQ, Xu XL, Zhang W, Zeng XS, Sun JF, Chen H.
Int J Dermatol. 2021 Apr;60(4):497-502. doi: 10.1111/ijd.15372. Epub 2020 Dec 28.
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.
Stein T, Robak T, Biernat W, Robak E.
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.
